SUCCESSFULLY CONCLUDED THE PLACEMENT AMOUNTING TO € 4,105,000, AT THE OFFER PRICE OF € 2.00 PER SHARE.
TRADING TO BEGIN ON 21 MARCH 2023

Rome, March 17th, 2023 – Cube Labs S.p.A. (“Cube Labs” or “Company”) – an Italian venture builder in the healthcare technology sector – announced that today it has received fromBorsa Italiana S.p.A. (“Borsa Italiana”),  the notice regarding the admission to trading of its ordinary shares and warrants called “Warrant Cube Labs 2023-2025” on the Euronext Growth Milan market – Professional segment, a multilateral trading system organized and managed by Borsa Italiana S.p.A. dedicated to high-growth potential SMEs.

“We are extremely pleased to be able to open up our capital through listing on the stock exchange. Our Venture Builder business model, innovative, and also pioneering in Italy, is destined to welcome more and more investors,” said Filippo Surace, CEO and Founder of Cube Labs, adding, “This is an important milestone for the world of Italian scientific research as a step towards the capital markets, and the fundraising will allow us to continue the development of healthcare technologies, and to reward the work done by the team so far.”

The total amount of the placement, entirely through capital increase, amounts to approximately €4,105,000, with institutional, professional, and industrial sector operators participating.

The placed shares are 2,052,500 at a fixed price of € 2.00 per share for a total value of €4,105,000. The company’s capitalization on the first day of listing will be €34,105,000 with a float of 12.04%.

The operation also includes the issuance of 2,052,500 warrants to be assigned free of charge in the ratio of 1 (one) Warrant for every 1 (one) share subscribed in the placement. For details of prices and exercise windows, please refer to the “Warrant Cube Labs 2023-2025” Regulations.

Following the placement, the company’s share capital will amount to €568,416.67, composed of 17,052,500 ordinary shares with no nominal value.

The start of trading is scheduled to begin on 21 March 2023.

The Company has been assigned the following identification codes:

• Alphanumeric code:
  • Ordinary shares: CUBE          
  • Warrant: “Warrant Cube Labs 2023- 2025”,

• ISIN code
  • Ordinary shares: IT0005532483
  • Warrant: IT0005532608

• Minimum lot: 2.500 shares

***

In the listing process, Cube Labs is assisted by Mit Sim S.p.A., as Euronext Growth Advisor, EnVent Capital Markets Ltd., as Global Coordinator, ADVANT Nctm, as Legal Advisor, 4AIM SICAF S.p.A. and Ambromobiliare S.p.A. as Financial Advisors, Ria Grant Thornton S.p.A. as Audit Firm, Bernoni Grant Thornton S.p.A., as Tax Advisor, Clarkson Hyde, as Consultant responsible for the circulation of extra-accounting data, CDR Communication S.r.l. as Company Advisor for Investor Relations, and SEC and Partners as Company Press Office.

***

The official text is the Italian version of the document. Any discrepancies or differences arisen in the translation are not binding and have no legal effect. In case of any dispute on the contents, the Italian original version shall always prevail.

***

Cube Labs

Cube Labs is the Italian venture builder in the healthcare technology sector, created to bridge the gap between excellent academic science and the commercial Life Science market. Cube Labs creates new companies from comercially promising R&D and promotes innovation to transform pioneering science into healthcare solutions. Through its international network, Cube Labs collaborates with innovation stakeholder to transform outcomes for patients and accelerate the global transition to optimal health.

For further information, please visit the website: www.cube-labs.com

Cube Labs
Global Media Contact
Isil Guney
Tel: +90 5325027243
E-mail: i.guney@cube-labs.com

Investor Relations
Vincenza Colucci
E-mail: vincenza.colucci@cdr-communication.it
Marika Martinciglio
E-mail: marika.martinciglio@cdr-communication.it

Ufficio Stampa Italia di Cube Labs
Matteo Steinbach
Cell. +393461063989
E-mail: matteo.steinbach@secnewgate.it

Federico Ziglioli
Cell. +393331225959
E-mail: federico.ziglioli@secnewgate.it